TABLE 1.
Gene | Full name | Increase in transactivation (fold) aftera: |
Activity |
Immunity/inflammation | ||
---|---|---|---|---|---|---|
2 h | 4 h | NF-κB target | p53 | |||
Slpi | Secretory leukocyte peptidase inhibitor | 1.6 | 2.6 | Unknown | − | Yes |
Gdf15 | Macrophage inhibitory cytokine-1 | 1.5 | 2.4 | + | + | Yes |
ThyN1 | Thymocyte nuclear protein 1 | 3 | 1.9 | Unknown | − | |
Gpr77 | G protein coupled receptor 77 | 1.4 | 1.8 | + | − | Yes |
Aire | Autoimmune polyendocrinopathy | 1.5 | 1.7 | + | − | |
Jun | Jun oncogene | 1.3 | 1.6 | + | − | Yes |
Casp4 | Caspase 4/11 | 1.6 | 1.6 | + | − | Yes |
Ccl4 | Chemokine ligand 4 | 1.4 | 1.6 | + | − | Yes |
Rnd3 | Rho family GTPase 3 | 1.7 | 1.5 | + | + | Yes |
CSF1 | Macrophage colony-stimulating factor 1 | 1 | 1.5 | + | + | Yes |
Cxcl1 | Chemokine ligand 1 | 1 | 1.4 | + | + | Yes |
The fold increase in transactivation in P72 cells compared to that detected in R72 cells is depicted after 2 and 4 h.